Literature DB >> 15090802

HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1.

Danuta Pieniazek1, Mark Rayfield, Dale J Hu, John N Nkengasong, Vincent Soriano, Walid Heneine, Clement Zeh, Simon M Agwale, Charles Wambebe, Liliana Odama, Stefan Z Wiktor.   

Abstract

BACKGROUND: HIV-1 protease inhibitors (PI) have been used for treating HIV-2-infected persons but little is known about amino acid mutations associated with PI resistance in HIV-2 and whether they are similar to those seen in HIV-1.
OBJECTIVE: To determine the frequency of HIV-1 PI resistance-associated mutations in PI-naive HIV-2-infected individuals.
DESIGN: Using PCR, protease genes were amplified from 76 individuals, directly sequenced, phylogenetically subtyped, and translated into amino acids to analyze PI-associated major and minor mutations.
RESULTS: Of the 76 HIV-2 sequences, 68% belonged to subtype A and 32% to subtype B. All sequences contained at least four codon changes giving substitutions at 10, 30, 32, 36, 46, 47, 71 or 77. The frequency of these mutations was similar in subtype A and B viruses. Two major resistance-conferring mutations, 30N and 46I, were identified in one (1%) and 68 (89%) specimens, respectively. Minor mutations 10V/I, 32I, 36I, 47V, and 71V were predominant (89%-100%), followed by the rare mutation 77I (1%). Of the 76 strains, 89% harbored multiple PI resistance-associated substitutions comprising both the major 46I and minor mutations: 10V/I, 32I, 36I, 46I, 47V, 71V (76%); 10V, 32I, 36I, 46I, 47V (9%); and 10V, 32I, 36I, 46I, 47V 71V, 77I (1.3%), 10V, 32I, 46I, 47V, 71V (1.3%), and 10V, 30N, 32I, 36I, 46I, 47V, 71V (1.3%). The remaining 11% of the sequences had patterns with only minor mutations: 10V, 32I, 36I, 47V, 71V (9%) and 10V, 32I, 36I, 47V (1.3%).
CONCLUSIONS: The high frequency of multiple PI-associated substitutions represent natural polymorphisms occurring in HIV-2 strains of subtypes A and B. Phenotypic and clinical studies are needed to determine the relevance of these substitutions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15090802     DOI: 10.1097/00002030-200402200-00016

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  22 in total

1.  Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.

Authors:  Michel Ntemgwa; Bluma G Brenner; Maureen Oliveira; Daniela Moisi; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors.

Authors:  F Damond; F Brun-Vezinet; S Matheron; G Peytavin; P Campa; S Pueyo; F Mammano; S Lastere; I Farfara; F Simon; G Chene; D Descamps
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

Review 3.  Antiretroviral drug resistance in human immunodeficiency virus type 2.

Authors:  Michel L Ntemgwa; Thomas d'Aquin Toni; Bluma G Brenner; Ricardo J Camacho; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

4.  Revealing the dimer dissociation and existence of a folded monomer of the mature HIV-2 protease.

Authors:  John M Louis; Rieko Ishima; Annie Aniana; Jane M Sayer
Journal:  Protein Sci       Date:  2009-12       Impact factor: 6.725

5.  Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.

Authors:  Dana N Raugi; Robert A Smith; Selly Ba; Macoumba Toure; Fatou Traore; Fatima Sall; Charlotte Pan; Lindsey Blankenship; Alexandra Montano; Julia Olson; Ndeye Mery Dia Badiane; James I Mullins; Nancy B Kiviat; Stephen E Hawes; Papa Salif Sow; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

6.  GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.

Authors:  Nicole S Delino; Manabu Aoki; Hironori Hayashi; Shin-Ichiro Hattori; Simon B Chang; Yuki Takamatsu; Cuthbert D Martyr; Debananda Das; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

7.  In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.

Authors:  Sherie Masse; Xiaozhi Lu; Tatyana Dekhtyar; Liangjun Lu; Gennadiy Koev; Feng Gao; Hongmei Mo; Dale Kempf; Barry Bernstein; George J Hanna; Akhteruzzaman Molla
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

Review 8.  Diagnosis of Human Immunodeficiency Virus Infection.

Authors:  Bharat S Parekh; Chin-Yih Ou; Peter N Fonjungo; Mireille B Kalou; Erin Rottinghaus; Adrian Puren; Heather Alexander; Mackenzie Hurlston Cox; John N Nkengasong
Journal:  Clin Microbiol Rev       Date:  2018-11-28       Impact factor: 26.132

9.  Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa.

Authors:  Geoffrey S Gottlieb; Ndeye Mery Dia Badiane; Stephen E Hawes; Louise Fortes; Macoumba Toure; Cheikh T Ndour; Alison K Starling; Fatou Traore; Fatima Sall; Kim G Wong; Stephen L Cherne; Donovan J Anderson; Stefanie A Dye; Robert A Smith; James I Mullins; Nancy B Kiviat; Papa Salif Sow
Journal:  Clin Infect Dis       Date:  2009-02-15       Impact factor: 9.079

10.  HIV type 2 protease, reverse transcriptase, and envelope viral variation in the PBMC and genital tract of ARV-naive women in Senegal.

Authors:  Geoffrey S Gottlieb; Stephen E Hawes; Kim G Wong; Dana N Raugi; Habibatou D Agne; Cathy W Critchlow; Nancy B Kiviat; Papa Salif Sow
Journal:  AIDS Res Hum Retroviruses       Date:  2008-06       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.